This is a Phase IIa, randomized, double-blind, placebo controlled trial. Subjects for
participation in this study will be identified by the Investigator based on their Clinical
Dementia Rating score which will be completed as part of standard practice. Patients meeting
the criteria for early Alzheimer's disease will be considered for study participation, with
the Investigator taking the additional inclusion/exclusion criteria into consideration. Up to
40 subjects will be enrolled. Subjects participating in the study will be randomized to
receive either gummies containing L-Serine or placebo gummies, with the Investigator and
study staff blinded to the group assignments.
Phase:
Phase 2
Details
Lead Sponsor:
Aleksandra Stark Dartmouth-Hitchcock Medical Center
Collaborator:
Brain Chemistry Laboratories, Institute for Ethnomedicine